Natera,Inc. (NASDAQ:NTRA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Natera,Inc. (NASDAQ:NTRA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On March 15, 2017, the board of directors (the “Board”) increased the authorized size of the Board to nine members, creating a vacancy on the Board.

On March 15, 2017, upon the recommendation of the nominating and corporate governance committee, the Board appointed Ms. Gail Marcus to serve as a member of the Board, effective immediately, to fill such vacancy. Ms. Marcus will serve as a Class I director, with an initial term expiring at the 2019 annual meeting of stockholders. There is no arrangement or understanding between Ms. Marcus and any other persons to which Ms. Marcus was elected as a director. The Board has not appointed Ms. Marcus to any board committee at this time.

In connection with her appointment to the Board, Ms. Marcus will be entitled to receive cash and equity compensation consistent with that of the Company’s other non-employee directors. Such compensation is described in Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2015.

Ms. Marcus does not have any family relationships or related party transactions that are required to be disclosed under Item 404(a) of Regulation S-K.


About Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).

Natera, Inc. (NASDAQ:NTRA) Recent Trading Information

Natera, Inc. (NASDAQ:NTRA) closed its last trading session down -0.12 at 8.64 with 223,438 shares trading hands.